TScan Therapeutics
TCRX
66 hedge funds and large institutions have $272M invested in TScan Therapeutics in 2024 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 22 increasing their positions, 9 reducing their positions, and 5 closing their positions.
240% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 5
144% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 9
46% more capital invested
Capital invested by funds: $186M → $272M (+$86.3M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
22% more funds holding
Funds holding: 54 → 66 (+12)
5.36% more ownership
Funds ownership: 73.28% → 78.64% (+5.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$3.07M |
| 2 |
LCM
Laurion Capital Management
New York
|
+$1.9M |
| 3 |
Millennium Management
New York
|
+$1.84M |
| 4 |
Goldman Sachs
New York
|
+$1.45M |
| 5 |
TAM
Tocqueville Asset Management
New York
|
+$1.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$252K |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
-$177K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$157K |
| 4 |
Stifel Financial
St. Louis,
Missouri
|
-$120K |
| 5 |
VF
Virtu Financial
New York
|
-$107K |
TCRX Hedge Fund Activity: Q1 2024 in Review
66 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q1 2024, worth a combined $272M — up 46% from $186M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new TCRX positions and 5 closed out — a net gain of 12 holders — while 22 added to existing stakes and 9 trimmed.
The largest buyer was Invesco, opening a new position worth an estimated $3.07M. The largest seller was 683 Capital Management, exiting entirely with an estimated $252K sold.
- 66 institutional investors held TScan Therapeutics (TCRX) as of Q1 2024, up from 54 in Q4 2023.
- Funds reported $272M of TScan Therapeutics stock for Q1 2024, up 46% quarter-over-quarter.
- 17 funds opened new TScan Therapeutics positions in Q1 2024 and 5 closed out, a net change of +12 holders.
- The largest TScan Therapeutics buyer in Q1 2024 was Invesco, an estimated $3.07M added.
- The largest TScan Therapeutics seller in Q1 2024 was 683 Capital Management, an estimated $252K sold.
Based on aggregated 13F filings for Q1 2024.